脐血移植特异性非复发死亡风险评估评分的开发
研究利用全国登记数据库回顾性分析4437例首次单份脐血移植受者,在训练队列(n=2687)中构建CoBRA评分,将受者分为低(0-4分)、中(5-7分)、高(8-11分)三组;验证队列(n=1750)中2年非复发死亡率分别为14.9%、25.5%、47.1%(P<.001),2年总生存率分别为74.2%、52.7%、26.3%(P<.001)。
要点
- CoBRA评分包含年龄≥55岁、HCT-CI≥3、男性受者、GVHD预防非他克莫司联合甲氨蝶呤、PS 2-4、HLA等位基因错配≥2、refined DRI高危、清髓性预处理、CD34+细胞剂量<0.82×10^5/kg。
- 验证队列中低、中、高危组2年非复发死亡率分别为14.9%、25.5%、47.1%(P<.001)。
- 验证队列中低、中、高危组2年总生存率分别为74.2%、52.7%、26.3%(P<.001)。
核心结论
- CoBRA评分可预测脐血移植后的非复发死亡风险及总生存。
- 需要进一步外部验证以确认CoBRA评分的意义。
研究设计与样本
- 利用全国登记数据库回顾性分析4437例首次单份脐血移植受者。
- 在训练队列(n=2687)中采用后向消除法构建CoBRA评分。
- 在验证队列(n=1750)中评估评分性能。
主要发现
- 训练队列中CoBRA评分包含年龄≥55岁(2分)、HCT-CI≥3(2分)、男性受者(1分)、GVHD预防非他克莫司联合甲氨蝶呤(1分)、PS 2-4(1分)、HLA等位基因错配≥2(1分)、refined DRI高危(1分)、清髓性预处理(1分)、CD34+细胞剂量<0.82×10^5/kg(1分)。
- 根据CoBRA评分将受者分为低(0-4分)、中(5-7分)、高(8-11分)三组。
- 验证队列中低、中、高危组2年非复发死亡率累积发生率分别为14.9%、25.5%、47.1%(P<.001)。
- 验证队列中低、中、高危组2年总生存率分别为74.2%、52.7%、26.3%(P<.001)。
关键数值与推荐
- CoBRA评分项目及分值:年龄≥55岁(2分)、HCT-CI≥3(2分)、男性受者(1分)、GVHD预防非他克莫司联合甲氨蝶呤(1分)、PS 2-4(1分)、HLA等位基因错配≥2(1分)、refined DRI高危(1分)、清髓性预处理(1分)、CD34+细胞剂量<0.82×10^5/kg(1分)。
- 风险分组:低危0-4分,中危5-7分,高危8-11分。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步外部验证以确认CoBRA评分的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Higher rate of nonrelapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graft sources, a UCBT-specific NRM risk assessment system is required. Thus, in this study, we sought to develop a UCBT-specific NRM Risk Assessment (CoBRA) score. Using a nationwide registry database, we retrospectively analyzed 4437 recipients who had received their first single-unit UCBT. Using the backward elimination method, we constructed the CoBRA score in a training cohort (n = 2687), which consisted of recipients age ≥55 years (score 2), hematopoietic cell transplantation-specific comorbidity index ≥3 (score 2), male recipient, graft-versus-host disease prophylaxis other than tacrolimus in combination with methotrexate, performance status (PS) 2 to 4, HLA allele mismatch ≥ 2, refined Disease Risk Index high risk, myeloablative conditioning, and CD34+ cell doses < 0.82 × 105/kg (score 1 in each). The recipients were categorized into 3 groups: low (0-4 points), intermediate (5-7 points), and high (8-11 points) groups according to the CoBRA score. In the validation cohort (n = 1750), the cumulative incidence of NRM at 2 years was 14.9%, 25.5%, and 47.1% (P < .001), and 2-year overall survival (OS) was 74.2%, 52.7%, and 26.3% (P < .001) in the low, intermediate, and high groups, respectively. In summary, the CoBRA score could predict the NRM risk as well as OS after UCBT. Further external validation will be needed to confirm the significance of the CoBRA score.
引用
- Okada Y, Usui Y, Hayashi H, et al. Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score. Blood Adv. 2024. PMID: 38163321. doi:10.1182/bloodadvances.2023011837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。